drugset
drugset / Trial / NCT02977208

Impact of Polymorphisms of OCT2 and OCTN1 on the Kinetic Disposition of Gabapentin in Patients Undergoing Chronic Use

NCT02977208 ↗

Phase 4 Completed 66 enrolled São Paulo State University University of Sao Paulo · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study aims to evaluate the influence of genetic polymorphisms of OCTN1 and OCT2 and other possible covariates on the kinetic disposition of GAB in patients undergoing GAB chronic treatment. Thus, patients treated with GAB, for at least one week, are being investigated.

Timeline

Start
2016-09
Primary completion
2018-02
Completion
2018-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Gabapentin Small molecule — —

Indications

chronic pain syndrome epilepsy